Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: The Belgian FExT study

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2485-2501

  Mets, Tony ^a   Vandewoude, Maurits ^b   Jacquy, Jean ^c,d   Deblander, Anne ^e   MacDonald, Karen ^f   Sloesen, Anne ^e   Abraham, Ivo ^f,g,h,i  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

^d UNIVERSITY OF MONS   (Belgium)

^e Novartis Pharma   (Belgium)

^f Matrix45 ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

Author keywords

Alzheimer's disease; Evidence based medicine; Outcomes research; Pharmacoepidemiology; Rivastigmine; Treatment effectiveness

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BELGIUM; CAREGIVER; CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG DOSE TITRATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENERAL HEALTH QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHIATRY; PATIENT ATTITUDE; PHARMACOEPIDEMIOLOGY; POST HOC ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES;

EID: 35648935963     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X226375     Document Type: Article

References (47)

1. Frisoni G. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J Neurol 2001;248:551-7
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593
3. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of Cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64
4. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of Neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289:210-6
5. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomized controlled trials. Int J Geriatr Psychiatry 2005;19;624-33
6. Farlow MR, Small GW, Quarg P, et al. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 1005;20:192-7
7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403
8. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15
9. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27
10. Rösler M, Retz W, Retz-Junginger P, et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998;11:211-6
11. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicenter open-label study. Euro Neuropsychopharmacol 2000;10:195-203
12. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33
13. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-4
14. Farlow MR, Lilly ML. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatrics 2005;5:3. Available from http://www.biomedcentral.eom/ 1471-2318/5/3 [Last accessed 23 June 2007]
15. Lilly ML, Farlow MR. Rivastigmine: an open-label, observational study of behavioral symptoms identified as most troubling by caregivers of patients with Alzheimer's disease. J Am Psychiatric Nurs Assoc 2005;11:293-7
16. Lopez OL, Becker JT, Saxton J, et al. Alteration of clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83-7
17. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59:817-22
18. Gillette-Guyonnet S, Andrieu S, Cortes F, et al. Outcome of Alzheimer's disease: potential impact of Cholinesterase inhibitors. J Gerontol: Med Sci 2006;61A:516-20
19. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and related dementias of late life. Am J Psychiatry 1997;154(Suppl):1-39
20. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66
21. National Institute for Clinical Excellence. Technology appraisal guideline number 19. Donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease. London: NICE, 2001
22. Santaguida PS, Raina P, Booker L, et al. Pharmacological treatment of dementia. Evidence report/technology assessment No. 97 (prepared by McMaster University Evidence-Based Practice Center under Contract 290-02-0020). Publication #04-E018-2. Rockville (MD): Agency for Healthcare Research and Quality, 2004
23. Rabins PV. Guideline watch: practice guideline for the treatment of patients with Alzheimer's disease and related dementias of late life. Washington (DC): American Psychiatric Association, 2006. Available from http://www.psych.org/psych_pract/treatg/pg/Alzheimers.watch.pdf [Last accessed 23 June 2007]
24. Pelosi A, McNulty SV, Jackson GA. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ 2006;333:491-3
25. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55
26. National Institute for Clinical Excellence. Technology appraisal guidance 111. Donepezil, rivastigmine, and galantamine (review) and memantine for the treatment of Alzheimer's disease. London: NICE, 2006
27. Zarit SH, Orr NK, Zarit JM. The hidden victims of Alzheimer's disease: families under stress. New York: New York University Press, 1985
28. Lingler JH, Matire LM, Schulz R. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc 2005;53:983-90
29. Eddy DM. Evidence-based medicine: a unified approach. Health Aff 2005;24:9-17
30. Timmermans S, Mauck E. The promises and pitfalls of evidence-based medicine. Health Aff 2005;24:18-28
31. Folstein MF, Folstein SE, McHugh PR. Mini-Mental Test: a practical method for grading the cognitive state of patient for the clinician. J Psychiatr Res 1975;12:189-98
32. Katz S, Ford AB, Moskowitz RW, et al. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-9
33. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86
34. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(Suppl 6):S10-6
35. Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9
36. Goldberg DP. The detection of psychiatric illness by questionnaire (Maudsley monograph No. 21). Oxford: Oxford University Press, 1972
37. Salmon DP, Thai LJ, Butter N, et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-30
38. Tukey JW. Exploratory data analysis. Menlo Park, CA: Addison Wesley, 1977
39. De Geest S. Basel assessment of adherence scale. Leuven, Belgium: Leuven Research and Development, 2000
40. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-9
41. Mayeux R, Sano M. Treatment of Alzheimer's disease. New Engl J Med 1999;341:1670-9
42. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-51
43. Scott WK, Edwards KB, Davis DR, et al. Risk of institutionalization among community long-term care clients with dementia. Gerontologist 1997;37:46-51
44. Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics 2005;23:227-42
45. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New Engl J Med 2006;355:1525-38
46. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
47. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92